Application of 1 type receptor antagonist of angiotensin II in treating tumour

An angiotensin and receptor antagonist technology, applied in the field of medicine, can solve problems such as leukopenia, patients' susceptibility to infectious diseases, and bleeding

Inactive Publication Date: 2009-12-30
陈志龙
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compared with surgical treatment and radiotherapy, chemotherapy not only kills local cancer cells, but also kills metastatic lesions throughout the body, but chemotherapy is not a panacea, and its own huge toxicity greatly limits the curative effect
Chemotherapy will kill white blood cells in the bone marrow, causing leukopenia, making patients susceptible to infectious diseases. Chemotherapy drugs will also affect the ability of bone marrow hematopoietic cells and platelet production, causing patients to encounter very slight injuries, and also cause bleeding or internal bleeding. In addition, secondary tumors from chemotherapy may appear many years later

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1: the preparation of therapeutic agent

[0037] The therapeutic agents used in the present invention are commercially available various sartan drugs, which are dissolved in phosphate buffered saline (PBS), stored in a refrigerator at 4° C., and diluted into working solutions of different concentrations with culture medium when used. Losartan: Tablet, produced by Hangzhou Modong Pharmaceutical Co., Ltd., approved by the State Drug Administration: X20000371, batch number: 01067; : Capsule, produced by Guangdong Hexin Pharmaceutical Co., Ltd., Zhunzi: X20000546; Eprosartan: tablet, produced by Hangzhou Keben Pharmaceutical Co., Ltd.; candesartan: tablet, produced by Hangzhou Keben Pharmaceutical Co., Ltd. ; Telmisartan: tablet, Zhejiang Jinliyuan Pharmaceutical Co., Ltd., approved by the State Drug Administration: H20041252; Olmesartan: tablet, produced by Hangzhou Keben Pharmaceutical Co., Ltd.

Embodiment 2

[0039] 1. Inhibitory effect of angiotensin II type 1 receptor antagonist on the growth of human liver cancer HepG2 cells in vitro

[0040] Tested cells: human liver cancer Hep G2 cells

[0041] Drugs tested: losartan, valsartan, irbesartan, eprosartan, candesartan, telmisartan, olmesartan

[0042] Experimental procedure: After the cells in the logarithmic growth phase were digested with trypsin, the cell concentration was adjusted to 5×10 with RPMI 1460 full medium 7 / L, 100 μL (5×10 3 ), at 37°C, 5% CO 2 Incubate overnight at saturated humidity. On the next day, add 100 μL of 500 μmol / L losartan, 100 μL of 500 μmol / L valsartan, 100 μL of 500 μmol / L irbesartan, 100 μL of 500 μmol / L eprosartan, 100 μL of 500 μmol / L candesartan, 500 μmol / L telmisartan 100μL, 500μmol / L olmesartan 100μL, with no drug as the control group, with 25mg / L cisplatin solution (DDP) as the positive control group, each group set 4 duplicate wells, cultured 24 , 48, 72h, discard the suspension 4-6h be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a new application of 1 type receptor antagonist of angiotensin II in treating tumour. Angiotensin II (Ang II) is the foremost effector of rennin-angiotensin system (RAS), the 1 type receptor of the Ang II plays an important role in propagation, migration and infiltration of tumour cells as well as in tumour angiogenesis. The 1 type receptor antagonist of the Ang II can effectively inhibit propagation and migration of tumour cells of various solid tumours such as prostate cancer, pancreatic cancer, liver cancer, gastric cancer, renal cancer and the like as well as tumour angiogenesis.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of sartan drugs in antitumor. Background technique [0002] According to WHO statistics, among the more than 5 billion people in the world, an average of 6.9 million people die from malignant tumors each year, and 8.7 million new cases occur, and the number is still increasing year by year. The situation in China is basically the same. In the past 20 years, the proportion of malignant tumors among the causes of death has risen from 12.6% to 17.9%. Therefore, governments, research institutions and pharmaceutical companies of various countries have long attached great importance to tumor research and anti-tumor drugs, and significant progress has been made in the research of anti-tumor drugs. [0003] Chemotherapy of tumors is a method of treating tumors by oral administration or injection of one or several chemical drugs. Compared with surgical treatment and radiotherapy,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P35/00
Inventor 陈志龙达雅静丁志楼
Owner 陈志龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap